Food Allergy Treatment Market By Product Type (Antihistamines, Epinephrine Auto-Injectors, Immunotherapy Products, Corticosteroids, Leukotriene Receptor Antagonist, Food Allergy Desensitization Therapy, Probiotics, Others), By Diagnosis (Skin Prick Test, Blood Test, Oral Food Challenge, ImmunoCAP Testing, Other), By Allergy Type (Peanut Allergy, Milk Allergy, Egg Allergy, Fish and Shellfish Allergy, Wheat Allergy, Other), and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Food Allergy Treatment market accounted for USD 7.52 Billion in 2024 and is expected to reach USD 18.0 Billion by 2035, growing at a CAGR of around 8.25% between 2025 and 2035. The Food Allergy Treatment Market is centered primarily on the advancement and monetization of administrative or medicinal approaches a person or organization can take to treat food allergies. Food allergies are a condition where people's immune system reacts to proteins in certain foods; severe effects may include anaphylaxis, which affects millions of people across the globe.

This market encompasses oral immunotherapy, allergy vaccines, biotherapy agents, biologic drugs, and allergen-specific immunotherapy intended to decrease the allergic response of the human body. Businesses are investing in research to introduce long-lasting therapies.

Report Scope:

Market Dynamics

The increasing global prevalence of food allergy treatment accelerates the demand

Food allergies, which affect people of all ages, but especially children, have become more common worldwide in recent years. Changes in people's lives, genetic makeup, and physical surroundings all contribute to the rise of food allergies. The public is extremely interested in food allergies, and as their prevalence has grown, so has the demand for effective management and treatment strategies. Food allergies require ongoing care and attention because they can cause serious side effects, including anaphylactic responses.

It has emerged as a health issue that has raised public awareness and prompted medical professionals to develop novel treatments, medications, or diagnostic tools. Third, there is proof that food allergies are becoming less of a problem in affluent nations and are progressively making their way to underdeveloped countries, which will increase the need for allergy treatments even more. As a result, the market for food allergy treatments is expanding to accommodate more patients, and new developments are being made to make life easier for those who suffer from food allergies.

Growing research in immunotherapy expands allergy treatment options significantly

Immunotherapy has become an innovative treatment method to cure and prevent food allergies, numerous research studies have also been conducted on immunotherapy for food allergies. This type of treatment involves desensitization of the immune system to the different allergens where the patient can be able to take food that initially caused allergic reactions. As the number of clinical studies and development of allergy immunotherapy increases, new methods including OIT, EPIT, and SLIT have emerged on the market. These innovative approaches offer a new glimmer of hope to patients who lack so many treatment options, to at least help them manage or even eliminate the effects of their food allergies.

The extension of immunotherapy reveals better opportunities for food allergy patients as it increases the number of treatment approaches and improves their efficacy. Further, there exist promising approaches to create combinations of completely different allergens or reach other portions of the immune system, which can change the way of treatment of food allergies. Since various immunotherapy treatments are receiving clinical trial evidence showing their efficacy and safety, there is also a projection for early regulatory permissions that make these treatments available to the large public.

Limited availability of allergy treatment specialists in underserved regions

In many developed or other regions, there are usually no adequate health facilities or human resources that may offer services for treating food allergy cases. Immunologists and allergists who diagnose and treat patients with allergies are unevenly distributed, with numerous practitioners in urban areas but few in rural and, consequently, low-income patients may not receive proper care. Many patients experience a delay in getting a diagnosis, poor management of food allergies, and other potentially life-threatening reactions that could have been prevented had they received the required professional attention. In addition, low levels of knowledge regarding food allergies and related prevention in these areas can assume a negative role in early diagnostics.

This access discrepancy becomes a significant bottleneck of enhanced food allergy management as the market expands for treatment options. This puts a call for increased coverage, especially through the healthcare service providers, the embrace of telemedicine services, and the need to produce more training programs for allergists. If this access challenge persists, the innovative food allergy treatments optimal use will not be attained in such regions, slowing overall market expansion.

Personalized treatments offer growth potential in allergy treatment management

They provide a personalized product offer based on the client's profile; customized therapies are growing in popularity in the food allergy treatment market. Personal treatments result in more precise and effective interventions than traditional standard treatment programs, which only include group therapies and ignore the patient's unique genetic predispositions, allergies, or even the functioning of their immune system. Given that different people may experience food allergies at various times and with varying degrees of sensitivity to therapy, this method is helpful.

The market for allergy therapies is growing because of advancements in genetic testing and biomarkers, which also require more specialized allergy treatments for those with food allergies before their conditions worsen. There is a lot of potential for higher per-patient therapeutic penetration for food allergies in terms of bettering patients' quality of life and providing pharmaceutical companies with more sophisticated financial opportunities as the healthcare industry gradually shifts to customized treatment.

The development of advanced allergy management vaccines enhances treatment options

The management of food allergies is being drastically changed by the upcoming immunologic modification of allergens and related items, which can offer long-lasting treatment approaches. To reduce the severity of the reaction and, in some cases, result in permanent desensitization, these vaccinations aim to alter the properties of the immune response to specific food allergens. In contrast to traditional medicine, which suppresses the symptoms of an allergic reaction, allergy vaccines find the issue as a disease and treat it by immunizing.

This is especially true as the only options open to those with severe food allergies, such as those to peanuts or tree nuts, are to avoid them or take emergency precautions. A more proactive or preventive strategy for treating allergies is promised by the development of novel allergy vaccinations that produce longer-lasting effects with fewer side effects. Numerous vaccines are in the early phases of development, and clinical trials and research are going ahead at full speed. As these vaccinations gain more acceptance, they may become a mainstay of contemporary food allergy treatment, broadening the current spectrum and opening new avenues for sufferers worldwide. Over the coming years, the market for food allergy therapies will grow significantly due to the development of such treatments.

Industry Experts Opinion

“The way medicine is typically looked at is we try to create products that handle symptoms, not the underlying root cause of the disease. Food allergies are one area where symptom treatment is inadequate. That is why inventors have struggled, because they approach it from symptom management, rather than getting to the root.”

• Meenal Lele, Founder and CEO, Lil Mixins.

Segment Analysis

Based on product type, immunotherapy includes immunotherapy products, biologic drugs, OIT, and EPIT. There is an excessively big market share in Immunotherapy products being developed to reduce the hypersensitivity of an immune system to specific allergens. Monoclonal antibiotics and other biological agents are becoming the usual method of managing severe allergic reactions. OIT is another product type based on the desensitization of patients to allergens, following which gradual exposure to allergens is used to build tolerance, and new food products free of these allergens are currently being developed for consumption by individuals with food allergies.

Based on the type of allergy, the Food Allergy Treatment Market is segmented into peanut allergy, milk allergy, egg allergy, tree nut allergy, and seafood allergy, among several. Peanut allergies are one of the most common and severe, which creates the need for personalized treatment. Milk and egg allergies are most common among children and there are treatments for younger generations. Allergies are specific to certain allergens, and therefore, the treatment plan is always unique, depending on the form of allergy, necessities for treating an acute phase, and preventive measures to enhance the quality of patients’ lives. This segmentation proves to be of much significance in finding the patients’ requirements and directs the development of products necessary for diverse types of allergic complaints.

Regional Analysis

North America is the Leading Food Allergy Treatment Market, especially the United States because of the high incidence of food allergy and sound health facilities. Significant drivers involve immunotherapy and biological therapies such as monoclonal antibodies and extensive usage of epinephrine auto-injectors for the treatment of an allergic reaction. A detailed analysis of the key drivers affecting market growth consists of heightened awareness, efficient diagnosis, and additional recognition by the authorities of innovative therapeutic methods.

Asia-Pacific is the fastest-growing region for the Food Allergy Treatment Market and the most rapidly advancing area due to the rising prevalence of children’s food allergies, higher healthcare expenditures, and the enhanced concern for better access to allergy therapies. The population in countries such as China and India is being diagnosed with food allergies at an impressive rate, presenting a large market for food allergy treatments and products.

Competitive Landscape

Competitors include big pharma manufacturers like Sanofi Company, AbbVie Company, and Viatris among others, and Biotech manufacturers including Aimmune Therapeutics and DBV Technologies, among others. Concerning innovation, the most relevant therapies include oral immunotherapy (such as Palforzia for peanut allergies), epicutaneous immunotherapy (like Viaskin peanut patch), and biologics, including monoclonal antibodies (like omalizumab).

However, several issues, for instance, the safety and efficacy of the products, remain a big challenge. The market is also concerned with the regulation that to approve the therapies, they must go through clinical trials. The North American market dominates the current scenario, but the European and Asia-Pacific markets are also on the ascending path in terms of demand for the treatment of food allergies.

Food Allergy Treatment Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In October 2024, DBV Technologies announced positive regulatory updates for its Viaskin Peanut patch in the U.S. and Europe. The FDA has agreed to an Accelerated Approval pathway for the patch in toddlers aged 1-3 years, contingent on a six-month safety study starting in Q2 2025. Meanwhile, the EMA confirmed a pathway for approval in children aged 1-7 years. DBV also reported strong enrollment for the VITESSE Phase 3 study in children aged 4-7, with topline results expected in Q4 2025.
• In July 2024, Stallergenes Greer announced FDA approval for Palforzia oral immunotherapy to treat peanut allergy in toddlers (ages 1-3). The approval expands upon the 2020 FDA approval for ages 4-17. The decision follows the successful Phase 3 POSEIDON study, which demonstrated Palforzia's efficacy and safety in young children. Stallergenes Greer bought Palforzia in September 2023 and is transitioning it into their allergen immunotherapy portfolio.

Report Coverage:

By Product Type

• Antihistamines
• Epinephrine Auto-Injectors
• Immunotherapy Products
• Corticosteroids
• Leukotriene Receptor Antagonists
• Food Allergy Desensitization Therapy
• Probiotics
• Other

By Diagnosis

• Skin Prick Test
• Blood Test
• Oral Food Challenge
• ImmunoCAP Testing
• Others

By Allergy Type

• Peanut Allergy
• Milk Allergy
• Egg Allergy
• Fish and Shellfish Allergy
• Wheat Allergy
• Other

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Nestlé Health Science
• Aimmune Therapeutics
• DBV Technologies
• Sanofi
• Regeneron Pharmaceuticals
• Stallergenes Greer
• Eli Lilly and Company
• Novartis
• Argenx
• Peanut Corporation of America
• Bausch Health Companies
• Horizon Therapeutics
• Allergenis
• MedImmune
• Theravance Biopharma
• Mylan Pharmaceuticals
• Immunovant

Frequently Asked Questions (FAQs)